This is to inform that due to some circumstances beyond the organizer control, "3rd Edition of International Precision Medicine Conference" (IPMC 2023) scheduled during April 24-26, 2023 in Orlando, Florida, USA has been postponed. The updated dates and venue will be displayed shortly.
Your registration can be transferred to the next edition, if you have already confirmed your participation at the event.
For further details, please contact us at precision-medicine@magnusconference.com or call + 1 (702) 988 2320.
Personalized cancer medicine is based on research into human genes and cancer genes. These investigations have aided in the development of more effective treatments. They’ve also used genetic data to build cancer diagnostics and prevention methods. Every year, cancer takes the lives of millions of people. Standard treatments, such as chemotherapy or radiation, are only effective in a small percentage of patients because of disease heterogeneity. Tumors can have a variety of genetic origins and may express various proteins in different patients. Other methods of cancer treatment may have more side effects than personalized cancer medicine. This is due to the fact that it is intended to be more particular. A tailored treatment may have fewer side effects on healthy cells and more on cancer cells.
Title : Copper (II) complexes as potential anticancer agents
Salah S Massoud, University of Louisiana, United States
Title : Leveraging blockchain technology, edge computing and federated learning to enhance outcomes in precision medicine
Ingrid Vasiliu Feltes, MEDNAX, United States
Title : The new horizons in the patient- centered care for understanding of the reasons of its health problems – Psychosynthesis approach
Ewa Danuta Bialek, Institute of Psychosynthesis, Poland
Title : Hegazy theory for interpretation of human parthenogenesis: A new hypothesis
Abdelmonem Awad Hegazy, Zagazig University, Egypt
Title : Precision Oncology and Personalised Medicine: Innovative Technology for the Treatment of Colorectal Cancer
Huiqin Yang, ICON Clinical Research Ltd, United Kingdom
Title : The role of CD44v6 as a new immunotherapy target for urothelial cancer
Iris Adriana Maria Lodewijk, Institute of Biomedical Research, Spain